New Pain Inhibitor VER-01 Surpasses Opioids in Head-to-Head Clinical Comparison
In a Phase 3 program, the investigational drug based on a standardized cannabis extract not only showed better pain relief than opioids for chronic back pain but also had significantly better gastrointestinal tolerability, opening a new era of opioid-free analgesia.
A $250 Million Game: Why VER-01 vs. Opioids Is More Than Just a Drug Battle
[The Gist]: What's Really Happening
News agencies in late May 2026 were again flooded with headlines: "cannabis drug beats opioids." But if you think this is news from 2026, you're wrong—you're just rereading what happened back in October 2025, now with a fancy FDA label. On May 18, 2026, the FDA granted VER-01 Breakthrough Therapy designation. The media presents it as "another triumph." But I'll tell you what's really happening.
Vertanical spent $250 million and seven years of development to turn a specific cannabis strain into a standardized drug. And here's the result: in a head-to-head comparison with opioids, VER-01 reduced pain by 2.50 points versus 2.16, improved sleep by 2.52 versus 2.07, and most importantly, caused four times fewer cases of constipation (p=0.007).
The inside scoop no one is discussing: the real victory here is not in pain relief. A difference of 0.34 points on a 10-point scale is barely clinically significant. The victory is in the gut. Opioid-induced constipation is the silent killer of compliance. Patients stop opioids not because they provide poor pain relief, but because they can't have a bowel movement for two weeks. VER-01 almost completely eliminates this problem.
Timeline and Context
The race for VER-01 to become the "first non-psychiatric cannabis drug since Epidiolex" began long before May 2026:
- September 2025 — Publication in Nature Medicine of a placebo-controlled study on 820 patients. VER-01 showed a 2.9-point reduction in pain at 6 months.
- September 30, 2025 — Publication in Pain & Therapy of a head-to-head comparison with opioids in 384 patients.
- May 18, 2026 — FDA grants Breakthrough Therapy Designation.
- Expected in the coming weeks (May-June 2026) — First marketing approval in Europe under the name Exilby.
- 2027 — First Phase 3 results in the US.
- 2028 — NDA submission to the FDA.
Importantly, the FDA decision coincided with a historic moment: medical cannabis was officially moved to Schedule III in the US. This means that if VER-01 gets approval, it automatically enters standard hospital formularies and insurance reimbursement systems.
Who Wins and Who Loses
Winners:
- Vertanical / FUTRUE Group (Dr. Clemens Fischer, CEO) — The German private player just got a free ticket to the big leagues of M&A. The company's estimated value could soar from the current ~$500 million to $2-3 billion by the time of NDA submission in 2028.
- Patients with chronic back pain — There are over half a billion worldwide. VER-01 is particularly effective in patients with a neuropathic pain component and those suffering from severe forms—where the difference in pain relief reaches 0.58 points.
- Charles Argoff (Albany Medical College) — The professor and co-author of the study will now become the leading voice in any discussion about VER-01. His consulting fees in 2026-2027 could reach hundreds of thousands of dollars.
Losers:
- Laxative manufacturers — A market worth hundreds of millions of dollars, sustained by patients with opioid-induced constipation, begins to shrink.
- Vertex Pharmaceuticals (suzetrigine, Journavx) — Their non-opioid analgesic, approved by the FDA in 2025, now has a competitor in the same field. Suzetrigine doesn't have a constipation problem, but there are questions about efficacy—in trials, it didn't always outperform placebo.
- Opioid generic manufacturers — Teva, Amneal, Mallinckrodt. Their multibillion-dollar business on oxycodone and hydrocodone faces a long and painful contraction.
What the Media Isn't Telling You
First—a non-obvious insight: The head-to-head comparison of VER-01 with opioids isn't exactly a "fair fight." In the study, patients in the opioid group were allowed to receive "any commercially available opioids" chosen by the physician. This means the opioid group had a heterogeneous mix of drugs, doses, and regimens. And VER-01 still beat this "mix." But it also means we don't know how VER-01 compares to each opioid individually. Morphine, oxycodone, tramadol—all have different profiles. Perhaps against tramadol, the difference would be smaller.
Second: The article states that at 27 weeks, the differences in pain relief between VER-01 and opioids were not statistically significant. Statistical significance only appeared when analyzing the entire 6-month trajectory. This is an academic nuance, but it's important: the FDA typically looks at time-point endpoints, not area under the curve. The fact that the primary endpoint was not met at a fixed time point could have killed any other drug. But VER-01 is a special case.
Third: VER-01's safety profile includes dizziness, headache, fatigue, nausea, dry mouth, and somnolence. These effects were particularly pronounced in the first 3 weeks of titration. So a physician prescribing VER-01 must be prepared for the patient to call on day two and say, "I'm dizzy, I can't work." This is manageable, but it's an additional burden on the clinician.
Fourth—an insider's insight: Vertanical spent $250 million on developing VER-01 over 7 years. These are relatively modest figures by Big Pharma standards (Novartis spends $2-3 billion to bring a new drug to market). But they don't include marketing costs. When VER-01 hits the US market (2028), Vertanical will have to compete with Vertex, whose promotional budget for Journavx is hundreds of millions of dollars. Most likely, Vertanical will sell itself to one of the giants before it starts selling the drug on its own. Potential buyers: Pfizer (they have experience with cannabinoids), Novartis (looking for new platforms in neurology), or Jazz Pharmaceuticals (owners of Epidiolex).
Forecast: Next 30 Days and 90 Days
Next 30 days (through end of June 2026):
- Key event — First European approval in Germany in the coming weeks. VER-01 will hit the market under the name Exilby. This will be the world's first commercially available standardized cannabis drug for chronic pain.
- This will be followed by the mutual recognition procedure in the EU—France, Poland, Czech Republic, Spain will get access within 6-9 months.
- Price in Europe: I expect €300-400 per monthly course. This is comparable to generic opioids (€50-100 per month), but insurance systems will likely agree to pay extra for the absence of constipation.
Next 90 days (through end of August 2026):
- Vertanical will announce the start of the US Phase 3 (already planned for early 2026). The study will include 500+ patients, with results in 2027.
- Negotiations with the FDA on NDA design will begin. Key question: Will US regulators accept European data as a basis for approval, or will they require repeating all studies in the US? Given that Vertanical is launching a new Phase 3, it's the latter.
- Analysts from Bernstein or SVB Leerink will publish the first financial analysis of Vertanical. The company has no current data (it's private), but estimates will be based on comparisons with Epidiolex ($100 million per year) and suzetrigine (forecast $500 million-$1 billion). My estimate: VER-01 could achieve $300-500 million in peak sales.
Longer-term forecast (12-24 months):
- By the end of 2026, VER-01 will be approved in 5-7 European countries. First real-world data will come in early 2027.
- In 2027, results from expanded studies in neuropathic pain and fibromyalgia will be presented—this will significantly expand the potential market.
- NDA in the US in 2028, approval in 2029-2030. By then, the market will already be divided between Vertex and possibly other players. But VER-01 has a unique advantage—7 years of data and a manufacturing platform that cannot be quickly replicated.
Bottom line: VER-01 is not just a drug. It's the first time a pharmaceutical company has turned "weed" into a standardized, patented, clinically tested drug that outperforms the industry's gold standard. The next 18 months will show whether Vertanical can compete with Big Pharma on their turf. But one thing is certain: Dr. Clemens Fischer and his $250 million have just changed the rules of the game in chronic pain treatment.
— Editorial Team
